Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma

Ishido, Keinosuke; Kimura, Norihisa; Wakiya, Taiichi; Nagase, Hayato; Hara, Yutaro; Kanda, Taishu; Fujita, Hiroaki; Hakamada, Kenichi

doi:10.1245/s10434-021-10866-6

Cited by 11 publications

(9 citation statements)

References 76 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past decade, several cut-offs have been proposed to divide patients into early or late recurrence groups in resectable PDAC 17–19,25–31. A cut-off is necessary as early recurrence means that the surgery performed is likely to have been of little benefit to the patient.…”

Section: Discussionmentioning

confidence: 99%

“…In the past decade, several cut-offs have been proposed to divide patients into early or late recurrence groups in resectable PDAC. [17][18][19][25][26][27][28][29][30][31] A cut-off is necessary as early recurrence means that the surgery performed is likely to have been of little benefit to the patient. Groot et al was the first to statistically stratify patients into an early and late recurrence group using PRS for a large cohort of patients with resected PDAC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy

et al. 2022

View full text Add to dashboard Cite

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In addition, a value of 1 was assigned to all risk factors to construct a comprehensive correlation prediction model. Hence, the cumulative risk score for every patient in the test set was calculated by aggregating the applicable risk ratings [ 14 ]. The Hosmer and Lemeshow goodness-of-fit test was employed to assess the calibration and discrimination properties.…”

Section: Methodsmentioning

confidence: 99%

Receptor Positive Breast Lesions and Status of Axillary Lymph Node

Singhal

2023

Cureus

View full text Add to dashboard Cite

This study aimed to examine the axillary pathological condition through the development of an assessment framework for hormone receptor-positive breast cancer subsequent to neoadjuvant chemotherapy (NAC). Furthermore, the primary objective of this study was to examine the association between axillary status and breast tumors that are positive for hormone receptors following neoadjuvant chemotherapy. MethodologyThe present retrospective investigation encompassed a cohort including 300 individuals who were administered neoadjuvant chemotherapy before receiving surgical intervention. The data collection period for this study was from September 2021 to December 2022. All patients received neoadjuvant chemotherapy, per the guidelines established by the National Comprehensive Cancer Network (NCCN). We divided patients into two distinct groups: a test set of 250 patients and a validity set of 50 patients. Patients with no evidence of lymphoid involvement underwent a biopsy of sentinel lymph nodes (SLNB) and would have undergone axillary dissection if the biopsy results had indicated positive findings. A logistic regression analysis was employed to investigate the variables linked to the presence of residual positive axillary lymph nodes in the test set. Subsequently, a multivariate analysis was conducted on the variables that exhibited a p-value below 0.2 in the univariate study. In addition, a value of 1 was assigned to all risk factors to construct a comprehensive correlation prediction model. ResultsThe participants included in this study had a mean age and body mass index (BMI) of 46.24 ± 9.1 years and 25.8 ± 2.5 kg, respectively. The present investigation examined the presence of pathological axillary metastases in a cohort of 188 patients, which accounted for 62.55% of the total sample, by utilizing coreneedle biopsy. Furthermore, the incidence rates of individuals presenting with clinical T1 were reported as 14.6%, while 55.2% cases of T2, 17.8% cases of T3, and 13% cases of T4 tumors were reported, respectively. Of the overall occurrences, the prevailing histological subtype was invasive ductal carcinoma, accounting for 91.4% (222 out of 243) of the cases. Multiple criteria were identified as independent predictors of the presence of residual positive axillary lymph nodes. The factors under consideration encompass lymphovascular invasion (odds ratio= 7.108; 95% breast cancer stage (odd ratio = 5.025; 95%, HER2 negativity (odd ratio= 2.997), low Ki-67 expression (odd ratio = 4.231), and suspected positive axillary lymph nodes before surgical intervention. ConclusionThe present study presents a novel prediction model that integrates imaging and pathology data, aiming to assist patients and healthcare practitioners in evaluating the efficacy of NAC for hormone-receptor-positive breast tumors. The model holds particular significance for individuals who exhibit clinical positivity in their lymph nodes (LNs). Consequently, the model has the potential to provide guidance for the management of axillary lymph nodes and p...

show abstract

“…To develop a generalized axillary correlation prediction model, each factor was defined as 1 which indicated the risk score. Hence, the total risk score for each patient in the test set was obtained from the sum of the eligible risk scores [ 14 ]. This prediction model was subsequently validated in another randomly assigned group.…”

Section: Methodsmentioning

confidence: 99%

Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data

Qiu

Zheng

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Purpose. To develop a scoring system for hormone receptor-positive (HR+) breast cancer patients who are expected to achieve axillary pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). To confirm the correlation between axillary status and survival rate in HR+ breast cancer after NAC. Methods. Women from the Shanghai Jiao Tong University Breast Cancer Database (SJTU-BCDB) who underwent NAC for cT1-4N1-3M0 primary HR+ breast cancer between 2009 and 2018 were included in the study. In this case, patient follow up was performed until 2022 for those with complete data before and after NAC. The main outcome measures were the axillary pCR rate, overall survival (OS), and disease-free survival (DFS). The patients were randomly assigned to a test set (n = 175) and a validation set (n = 68) in a 7 : 3 ratio. A prediction risk score was then developed based on the odds ratios from the multivariate analysis of the test set (n = 175) before being validated in the validation set (n = 68). Finally, the Kaplan–Meier curves were used to explore the survival on this score system. Results. From the database, 243 women were included, and the median follow-up period was 47.5 months (95% confidence interval: 41.9–53.1). The axillary pCR rate was 18.9% (46 of 243), with the independent predictors of residual positive axillary lymph nodes (LNs) being lymphovascular invasion (LVI), breast conserving surgery (BCS), Ki67 < 14%, HER2 negativity, positive lymph nodes in ultrasound (US) before surgery, and stage III histological grade (All, P < 0.05 ). Using the above predictors of the model, the receiver operating characteristic (ROC) curve was used for calibration and inspection, with values for the test and validation sets being 0.847 ( P < 0.001 ; 95% CI: 0.769, 0.925) and 0.813 ( P < 0.001 ; 95% CI: 0.741, 0.885), respectively. The total risk score ranged from 0 to 6 for the multivariate analysis, and from this range, a risk score of 0–2 was defined as a low-risk group, while scores of 3–6 were defined as the high-risk one. By constructing the survival curve, it was found that the 5-year OS rates for the low-risk and high-risk groups were 89.0% and 84.2% (P = 0.236). Similarly, the 5-year DFS rates for the low-risk and high-risk groups were 80% and 68.5% (P = 0.048), respectively. In addition, axillary pathological stages were significantly correlated with the overall survival (OS) and disease-free survival (DFS) (All, P < 0.05 ). Conclusion. The prediction model showed good performance for HR + breast cancer. LVI, BCS, low Ki-67, HER2 negativity, suspected positive LNs before surgery, and stage III histological grade were all risk factors for residual positive axillary LNs. However, unlike pathological stages, achieving pCR in the axillary LNs does not affect the survival status.

show abstract

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma

Cited by 11 publications

References 76 publications

Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy

Early Recurrence After Resection of Locally Advanced Pancreatic Cancer Following Induction Therapy

Receptor Positive Breast Lesions and Status of Axillary Lymph Node

Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data

Contact Info

Product

Resources

About